SCHEMBL992628

SCHEMBL992628

C#CC1(O)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 1/20 0.41
RECQL P46063 1/20 0.39
NR1H2 P55055 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
EPHX2 P34913 1/20 0.37
CTSK P43235 1/20 0.36
EPHX1 P07099 1/20 0.36
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
RORC P51449 2/20 0.35
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5549521 0.87 USP2 (0.42) USP2SMN1; SMN2HPGDRECQLMEN1
SCHEMBL31496738 0.87 USP2 (0.39) USP2SMN1; SMN2HPGDRECQLNR1H2
SCHEMBL3192439 0.84 HPGD (0.44) USP2SMN1; SMN2HPGDRECQLMEN1
SCHEMBL2110226 0.83 USP2 (0.49) USP2SMN1; SMN2HPGDRECQLMEN1
SCHEMBL18535153 0.82 USP2 (0.43) USP2SMN1; SMN2HPGDRECQLNR1H2
SCHEMBL28956005 0.82 USP2 (0.43) USP2SMN1; SMN2HPGDRECQLNR1H2
SCHEMBL22983571 0.82 USP2 (0.43) USP2SMN1; SMN2HPGDRECQLNR1H2
SCHEMBL26641323 0.81 USP2 (0.42) USP2SMN1; SMN2HPGDRECQLNR1H2
SCHEMBL18588192 0.79 USP2 (0.41) USP2SMN1; SMN2HPGDRECQLNR1H2
SCHEMBL25289094 0.79 USP2 (0.41) USP2SMN1; SMN2HPGDRECQLNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4025575-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-12-17 EP disclosed
CN-114728918-B RIP1 inhibitory compounds and methods of making and using the same 里格尔药品股份有限公司 2025-06-17 CN disclosed
CN-120092003-A CDK protein degrading agents, pharmaceutical compositions and therapeutic uses 拜欧斯瑞克斯公司 2025-06-03 CN disclosed
EP-4025568-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-05-14 EP disclosed
EP-4025574-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-05-07 EP disclosed
CN-114728958-B RIP1 inhibitory compounds and methods of making and using the same 里格尔药品股份有限公司 2025-05-02 CN disclosed
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
EP-4474017-A2 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-11 EP disclosed
US-20240368119-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS, INC. 2024-11-07 US disclosed
CN-118619943-A Heteroaromatic ring compound, pharmaceutical composition and application thereof 上海艾力斯医药科技股份有限公司 2024-09-10 CN disclosed
US-8883778-B2 Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-8883778-B2 Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2448928-B1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS INC (US) 2014-08-13 EP disclosed
EP-2448928-B1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS INC (US) 2014-08-13 EP disclosed
US-20120232050-A1 Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2012-09-13 US disclosed
US-20120232050-A1 Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2012-09-13 US disclosed
US-20120232050-A1 Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2012-09-13 US disclosed
EP-2448928-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 Vitae Pharmaceuticals, Inc. (US) 2012-05-09 EP disclosed
WO-2011002910-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2011-01-06 WO disclosed
WO-2011002910-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368119-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIPK1, RIPK2, RIPK3 USP2 1082/4885SMN1; SMN2 1682/4885HPGD 3518/4885
US-20120232050-A1 Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSD3B1, HSD11B2 USP2 3535/4885SMN1; SMN2 4460/4885HPGD 74/4885
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 USP2 37/4885SMN1; SMN2 2626/4885HPGD 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.